New Kidney Cancer Drug

. . . Kidney cancer breakthrough. Phase III clinical trial data showed that a new drug, BAY 43-9006, developed by Onyxx (NasdaqNM:ONXX) and its partner Bayer, is able to slow the spread of advanced kidney cancer. Based on the strong data, the drug may be eligible for accelerated approval by the FDA, which can speed up the approval approval from two or more years to only one year.

From: www.SmallcapRecap.com